Our CEO Revital Rattenbach will attend the upcoming Biomed 2016 meeting, on May 24-26. Meet her there at the Pharmaseed’s booth #85 to discuss future partnerships.
4P Pharma’s CEO, Revital Rattenbach, and our business developer Luigi Formicola, will be attending the upcoming MEET2WIN meeting in Bordeaux, May 12-13 2016.
Contact us via the partnering platform to schedule a meeting and discuss future collaborations.
4P Pharma, SATT AxLR and IBMM have concluded a co-development agreement
Montpellier, December 1st 2015
In the context of an innovative medical drug development project for the treatment of cancers, called “Imiqualines”, the oncology-pharmaco-chemical and pharmaco-toxicological team of IBMM, SATT AxLR and 4P Pharma have concluded a co-development maturation agreement with a licensing option.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
4P-Pharma at Biomed 2016
Our CEO Revital Rattenbach will attend the upcoming Biomed 2016 meeting, on May 24-26. Meet her there at the Pharmaseed’s booth #85 to discuss future partnerships.
4P-Pharma at MEET2WIN 2016
4P Pharma’s CEO, Revital Rattenbach, and our business developer Luigi Formicola, will be attending the upcoming MEET2WIN meeting in Bordeaux, May 12-13 2016.
Contact us via the partnering platform to schedule a meeting and discuss future collaborations.
4P Pharma at BIO-Europe Spring 2016
4P Pharma team will be attending the upcoming BIO-Europe Spring 2016 on april 4 to 6 in Stokholm.
We are looking forward to meet potential partners there to discuss licensing-out opportunities of our abuse deterrent technologies 4P-003
Happy 2016 from 4P Pharma
Your good resolution for 2016:
Give your ideas a chance to become a reality with 4P Pharma!
Press release – 1st December 2015
4P Pharma, SATT AxLR and IBMM have concluded a co-development agreement
Montpellier, December 1st 2015
In the context of an innovative medical drug development project for the treatment of cancers, called “Imiqualines”, the oncology-pharmaco-chemical and pharmaco-toxicological team of IBMM, SATT AxLR and 4P Pharma have concluded a co-development maturation agreement with a licensing option.
EN: Press release 4P Pharma-SATT AxLR 011215
FR: Communiqué de presse 4P Pharma-SATT AxLR 011215 Press release 4P Pharma-SATT AxLR 011215
PRESS CONTACTS:
4P Pharma
Revital Rattenbach
1 rue du Professeur Calmette, 59000 Lille
revital@4p-pharma.com
Tel: +33 (0)9 50 72 97 68
Université de Montpellier
Anne Delestre
CC 07-003 Place Eugène Bataillon, 34095 Montpellier cedex 5
anne.delestre@umontpellier.fr
Tel: +33 (0)4 34 43 31 93
CNRS
Aurélie Lieuvin
1919 route de Mende, 34293 Montpellier cedex 5
aurelie.Lieuvin@dr13.cnrs.fr
Tel: +33 (0)4 67 61 35 10
AxLR SATT
Franck-Léopold Erstein
1000, Avenue Agropolis, 34394 Montpellier cedex 5
fle@axlr.com
Tel: +33 (0)6 07 28 21 43